Literature DB >> 22282446

Endovascular treatment of ruptured brain AVMs in the acute phase of hemorrhage.

W J van Rooij1, S Jacobs, M Sluzewski, G N Beute, B van der Pol.   

Abstract

BACKGROUND AND
PURPOSE: Patients with ruptured brain AVMs are at considerable risk of repeat hemorrhage, particularly when associated intranidal or flow-related aneurysms are present. There is controversy about the timing of diagnosis and treatment of patients with hemorrhagic stroke. We present our results of endovascular treatment of ruptured AVMs in the acute phase.
MATERIALS AND METHODS: Between January 2008 and March 2011, 23 patients (16 men, 7 women; mean age 42 years) with AVM-related hemorrhagic stroke were treated with endovascular techniques within 10 days of the ictus. There were 10 micro-AVMs (< 1 cm) and 1 single-hole pial fistula. In 9 patients, an intranidal or flow-related aneurysm was the likely cause of hemorrhage.
RESULTS: Complete obliteration of the AVM with Onyx was achieved in 13 of 23 patients (57%). Eight of the 13 AVMs were micro-AVMs and 3 had an intranidal aneurysm. Partial obliteration of the AVM was achieved in 10 of 23 patients (43%). In 6 of these 10 patients, an intranidal (n = 1) or flow-related aneurysm (n = 5) was obliterated with Onyx or coils. There were no complications of treatment. During a mean follow-up of 21 months in 22 surviving patients, no repeat hemorrhage occurred.
CONCLUSIONS: Endovascular treatment with Onyx in the acute phase cured most ruptured AVMs. All 9 AVM-associated aneurysms that were considered the source of hemorrhage could be excluded from the circulation. In patients with AVM-related hemorrhagic stroke, prompt angiographic diagnosis and treatment may improve prognosis by reducing repeat hemorrhage rate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282446      PMCID: PMC8013235          DOI: 10.3174/ajnr.A2995

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

Review 1.  EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force.

Authors:  J C Masdeu; P Irimia; S Asenbaum; J Bogousslavsky; M Brainin; H Chabriat; K Herholz; H S Markus; E Martínez-Vila; K Niederkorn; P D Schellinger; R J Seitz
Journal:  Eur J Neurol       Date:  2006-12       Impact factor: 6.089

Review 2.  Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy.

Authors:  Christian Stapf; Jay P Mohr; Jae H Choi; Andreas Hartmann; Henning Mast
Journal:  Curr Opin Neurol       Date:  2006-02       Impact factor: 5.710

3.  Brain AVM embolization with Onyx.

Authors:  W J van Rooij; M Sluzewski; G N Beute
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

Review 4.  Targeting cerebral arteriovenous malformations for minimally invasive therapy.

Authors:  Michael J Alexander; Marshall E Tolbert
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

5.  The natural history of unruptured intracranial arteriovenous malformations.

Authors:  R D Brown; D O Wiebers; G Forbes; W M O'Fallon; D G Piepgras; W R Marsh; R J Maciunas
Journal:  J Neurosurg       Date:  1988-03       Impact factor: 5.115

6.  Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: new management using Onyx.

Authors:  C Cognard; A C Januel; N A Silva; P Tall
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

7.  The rationale behind "A Randomized Trial of Unruptured Brain AVMs" (ARUBA).

Authors:  Christian Stapf
Journal:  Acta Neurochir Suppl       Date:  2010

8.  Arteriovenous malformations of the brain: natural history in unoperated patients.

Authors:  P M Crawford; C R West; D W Chadwick; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

9.  The natural history and predictive features of hemorrhage from brain arteriovenous malformations.

Authors:  Leodante da Costa; M Christopher Wallace; Karel G Ter Brugge; Cian O'Kelly; Robert A Willinsky; Michael Tymianski
Journal:  Stroke       Date:  2008-11-13       Impact factor: 7.914

10.  Endovascular occlusion of high-flow intracranial arteriovenous shunts: technical note.

Authors:  Willem Jan van Rooij; Menno Sluzewski
Journal:  Neuroradiology       Date:  2007-09-06       Impact factor: 2.804

View more
  5 in total

1.  Clinical features and endovascular treatment of intracranial arteriovenous malformations in pediatric patients.

Authors:  Tao Zheng; Qiu-Jing Wang; Ya-Qi Liu; Xu-Bo Cui; Yu-Yuan Gao; Ling-Feng Lai; Shi-Xing Su; Xin Zhang; Xi-Feng Li; Xu-Ying He; Chuan-Zhi Duan
Journal:  Childs Nerv Syst       Date:  2013-09-08       Impact factor: 1.475

2.  Ruptured brain arteriovenous malformations associated with aneurysms: safety and efficacy of selective embolization in the acute phase of hemorrhage.

Authors:  Francesco Signorelli; Benjamin Gory; Isabelle Pelissou-Guyotat; Jacques Guyotat; Roberto Riva; Frédéric Dailler; Francis Turjman
Journal:  Neuroradiology       Date:  2014-06-28       Impact factor: 2.804

Review 3.  Onyx(®) in endovascular treatment of cerebral arteriovenous malformations - a review.

Authors:  Maciej Szajner; Tomasz Roman; Justyna Markowicz; Małgorzata Szczerbo-Trojanowska
Journal:  Pol J Radiol       Date:  2013-07

4.  Successful perinatal management of a ruptured brain arteriovenous malformation in a pregnant patient by endovascular embolization followed by elective cesarean section: a single-case experience.

Authors:  Satoru Asano; Nahoko Hayashi; Shunsuke Edakubo; Maiko Hosokawa; Junko Suwa; Yutaka Saito; Shunsuke Ichi; Masuzo Taneda; Keiichi Katoh
Journal:  JA Clin Rep       Date:  2016-08-11

5.  Endovascular embolization of cerebral arteriovenous malformations: results of the Japanese Registry of Neuroendovascular Therapy (JR-NET) 1 and 2.

Authors:  Ryushi Kondo; Yasushi Matsumoto; Hidenori Endo; Shigeru Miyachi; Masayuki Ezura; Nobuyuki Sakai
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-29       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.